Summary

Many who experience a first demyelinating clinical event will convert to clinically definite multiple sclerosis. Data from the REFLEX and REFLEXION trials suggest that patients who receive early treatment with interferon beta 1-a will convert to multiple sclerosis later than patients who took placebo prior to receiving interferon beta 1-a.